Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297927 | 0.87 | KCNH2 (0.47) | L3MBTL1EPHX1HRH3ABCB1 | |
| SCHEMBL6346898 | 0.87 | KCNH2 (0.47) | L3MBTL1EPHX1HRH3ABCB1 | |
| SCHEMBL7834809 | 0.85 | HRH3 (0.35) | L3MBTL1HRH3EPHX2PTPRCABCB1 | |
| SCHEMBL7834806 | 0.85 | HRH3 (0.35) | L3MBTL1HRH3EPHX2PTPRCABCB1 | |
| SCHEMBL7834802 | 0.85 | HRH3 (0.35) | L3MBTL1HRH3EPHX2PTPRCABCB1 | |
| SCHEMBL7380787 | 0.83 | EPHX1 (0.38) | L3MBTL1EPHX1HRH3EPHX2ABCB1 | |
| SCHEMBL5342209 | 0.83 | EPHX1 (0.40) | L3MBTL1EPHX1HRH3ABCB1 | |
| SCHEMBL570857 | 0.81 | ABCB1 (0.34) | L3MBTL1EPHX1HRH3PTPRCABCB1 | |
| SCHEMBL11366947 | 0.80 | BTK (0.45) | L3MBTL1EPHX1HRH3EPHX2CA2 | |
| SCHEMBL7277999 | 0.80 | EPHX1 (0.46) | EPHX1HRH3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110117275-A | A kind of amino-metadiazine compound and its application in anticancer medicine | 杨诚 | 2019-08-13 | — | — | CN | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| EP-2619178-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | L3MBTL1 1325/4885EPHX1 995/4885HRH3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.